Pharma Focus Asia

Charles River Completes Acquisition of SAMDI Tech

Tuesday, January 31, 2023

Charles River announced the acquisition of SAMDI Tech. The acquisition is the culmination of an exclusive partnership between the companies started in 2018.

The acquisition of SAMDI Tech’s cutting-edge, high-throughput screening technology further strengthens Charles River’s drug discovery capabilities and enhances unique ability to better serve as an integrated partner to support clients’ early-stage research.

The combination of this end-to-end portfolio and industry-leading scientific expertise with SAMDI Tech’s innovative MS technology and expertise in assay solutions will significantly accelerate and augment clients’ discovery efforts by measuring biochemical activities and hit identification for virtually any small molecule drug target.

This acquisition provides Charles River’s clients a seamless access to the premier, label-free HTS MS platform to create a comprehensive, industry-leading library of drug discovery solutions and creates new business opportunities for Charles River family.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference